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Impact of births complicated by neural
tube defects (NTD)
Neural tube defects (NTDs) are congenital structural
abnormalities of the brain and vertebral column
caused by failure of neural tube closure [1]. They
include anencephaly (a lethal malformation),
encephalocele and spina bifida. Most pregnancies
with anencephaly are terminated in the first trimester
[2]. Spina bifida is usually compatible with life but
typically causes substantial disability in survivors.
Together with low birth weight, NTDs and other
congenital anomalies (2–3% of all livebirths) are the
leading cause of infant mortality and have remained
so for nearly 80 years. Worldwide, NTDs affect more
than 400,000 pregnancies a year and result in an esti-
mated 41,000 deaths and 2.3 million disability-
adjusted life years [3].
NTDs have a huge social and economic impact. It is
estimated that the average total lifetime cost for each
infant born with spina bifida is approximately USD
532,000, while estimated annual medical and surgical
costs for those living with spina bifida in the United
States exceed USD 200 million [4]. The accompanying
emotional and social problems of those affected by
spina bifida should not be underestimated.
Importance of folate
The aetiology of NTDs is multifactorial [5]. Adequate
intake of folic acid by women a few months before
pregnancy and during the first trimester can signifi-
cantly reduce the risk of fetal NTDs in both healthy
women and those at higher risk of having a child with
an NTD (diabetics, obese women, smokers, alcohol
consumers, antiepileptic drug users).
In 1991 the Medical Research Council Vitamin
Study [6] reported that periconceptional intake of 0.4
g/day folic acid reduced the recurrence of offspring
with non-syndromic NTDs by 72%. However, the
majority of NTD pregnancies are first occurrences [7].
A randomized trial in Hungary showed that pericon-
ceptional folic acid supplementation of 0.8 mg/day
significantly reduces first occurrence of NTDs [8].
Furthermore, there is increasing evidence that folic
acid may also protect against other congenital anoma-
lies, especially heart and orofacial defects [9].
The current worldwide accepted recommendations
for preconceptional folic acid supplementation may
be summarized as follows:
1. All women of childbearing age, if planning preg-
nancy, should consume 0.4 mg/day folate from
supplements, fortified foods, or both, in addition to
consuming food folate from a varied diet starting at
least 1 month before conception and through the
first 3 months of pregnancy.
2. Women at high risk of an NTD pregnancy (e.g.
maternal NTD, previously affected pregnancy, type
1 diabetes, use of antiepileptic drugs) should
consume 4 mg/day folic acid during the pericon-
ceptional period [10].
Traditional programmes for the prevention of poor
pregnancy outcomes commence with the first prena-
tal visit. The course of many poor outcomes, however,
is set before this first encounter. Organizations repre-
senting professionals and those working for the
prevention of both maternal and perinatal morbidity
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and mortality in all developed countries now recog-
nize that preconceptional health promotion is an
important part of women’s health care. During peri-
ods of rapid cell growth and division, such as
embryogenesis and fetal development, maternal
folate requirements increase dramatically.
By 56 days post-conception, any major structural
anomalies of the forming fetus have already devel-
oped. Closure of the neural tube occurs within just 28
days of conception, when most women are still
unaware of their pregnancy. Organogenesis in the
human embryo may be disrupted by environmental
factors, for example maternal habits (alcohol use and
smoking), underlying maternal disease (diabetes),
teratogenic drug exposure (vitamin A, antiepileptics)
and maternal nutritional status (folate levels) [11].
Preconceptional counselling and family planning
also help to prevent other poor pregnancy outcomes.
For example, the benefits of smoking cessation before
(or during) pregnancy for the prevention of low birth
weight, prematurity and placental abruption have
been well documented [12].
Currently, women of childbearing age can improve
their periconceptional folate status by (1) eating
unprocessed foods rich in natural folate, (2) eating
foods fortified with folic acid, (3) taking tablets
containing folic acid and (4) taking oral contracep-
tives with added folate (Table I).
Sources of folate
Unprocessed foods rich in natural folate
Barely any woman of childbearing age gets the
required daily amount of folate through unprocessed
foods rich in folate. Furthermore, natural folate is
heat-labile and prone to oxidative cleavage, such that
it may be destroyed by storage, processing and cook-
ing. The bioavailability of naturally occurring folate is
relatively low.
Foods fortified with folic acid
In 1998, the United States implemented mandatory
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Table I: Sources of folate supplementation in the periconceptional period [13–21].
Folate source Advantages Disadvantages
Folate from unprocessed foods Available in a variety of everyday foods Low bioavailability
Prone to oxygenation and food processing
Large amounts are needed to meet daily
folate requirements
Inefficient in patients with malabsorption
Foods fortified with folic acid Supplement to unprocessed foods Only 10% of reproductive-age women 
consume a highly protective amount of folate
Non-target population has long and 
unnecessary exposure to folate
Available only in certain countries
Folic acid tablets Cheap and available worldwide Poor compliance
Lack of awareness among women and  
health care providers
Oral contraceptives containing folate Optimal folate concentration in Suitable only for contraceptive pill users
periconceptional period that remains 
sufficient for several weeks after cessation 
of oral contraceptive
Protective folate concentration in cases of 
accidental pregnancy due to contraceptive 
failure or poor compliance
Suitable for both birth control and prevention
of birth defects (pregnancy planning)
Provides an opportunity to educate women 
during counselling about prevention of birth 
defects
Suitable for a targeted population without 
exposing those not at risk
fortification of bread, cereal, flour, corn meal, pasta,
rice and other grain products with folic acid to reduce
the occurrence of NTDs. Many countries followed
suit, including Canada, Australia, Chile and some
African and Asian countries. The rate of NTDs in the
United States dropped by 25% [13], while in Canada
food fortification has achieved a 46% reduction in the
prevalence of NTDs [14]. However, in Europe no
country has yet moved to compulsory food fortifica-
tion due to concerns about possible health risks
related to raising the folic acid intake of whole popu-
lations. Although food fortification in the United
States increased the serum folate levels of women of
childbearing age to an acceptable level, less than 10%
of these women reached a red blood cell folate level
(906 nmol/l) considered to be highly protective [15].
Therefore it is likely that women of childbearing age
need to consume additional folic acid through tablet
supplementation in order to reach protective red
blood cell folate levels.
The Irish experience showed that voluntary food
fortification can have a beneficial effect on public
health but cannot serve as a reliable public health
intervention. The Irish Food Safety Authority found
an undesired high blood folate status in a substantial
proportion of the population, especially among chil-
dren and the elderly [16]. Recent scientific develop-
ments linking excessive folic acid intake to an
increased risk of some developmental diseases,
degenerative disorders and even cancer emphasize
the need to ensure that individuals are not exposed to
excessive folic acid levels in the food supply [17].
Tablets containing folic acid
Despite growing public awareness about the impor-
tance of taking folic acid supplements, it is estimated
that a minority of women actually follow existing
recommendations and take folic acid supplements
during the advised period [18, 19]. There are several
reasons for this: a substantial proportion of women
are not aware of the recommendations, and in those
who are, compliance is poor.
It is estimated that over 50% of pregnancies are
unplanned. Once a pregnancy test is shown positive,
there is nothing much that can be done to prevent an
NTD, since the critical period of neurulation has
already occurred. Health care providers have their
own responsibility in this issue. Despite the fact that
in the United States more than 50% of women aged
18–39 access preventive health services, for the
majority a visit to the gynaecologist is no more than a
PAP smear, pelvic examination, ultrasonography 
or new or repeat prescription of contraceptives. A
recent study of nearly 600 obstetrician-gynaecolo-
gists and family physicians revealed that, in an
annual well-woman examination for women of child-
bearing age, 42% of obstetrician-gynaecologists
reported addressing multivitamin supplementation
‘occasionally’ or ‘never’ and 39% addressed the
specific nutrient folic acid ‘occasionally’ or ‘never’;
the figures for family practitioners were 55% and
59%, respectively [20].
“Once a pregnancy test is shown positive, 
there is nothing much that can 
be done to prevent an NTD, since 
the critical period of neurulation
has already occurred.”
There are several possible explanations for the lack
of attention to proven prevention strategies, such as
inadequate education of clinicians about preconcep-
tional health and pregnancy planning, poor apprecia-
tion of the incidence of unintended pregnancies and
congenital anomalies, and possible lack of confidence
that preconceptional health counselling can make a
difference. Women who are not considering preg-
nancy are believed to be even less likely to consume
folic acid on a regular basis, because their focus is on
preventing pregnancy rather than preventing birth
defects.
Adding folate to oral contraceptives: a new, targeted
approach in the primary prevention of NTDs
Oral contraceptives are predominantly used for
reversible contraception. An oral contraceptive with
added folate is already available in the United States.
At the end of September 2010 the US Food and Drug
Administration approved Beyaz® tablets, a combined
oral contraceptive that contains a folate (levomefolate
calcium 0.451 mg) in addition to drospirenone and
ethinylestradiol [21]. Beyaz® is based on the
approved product YAZ®, which contains the same
doses of estrogen and progestogen. Beyaz® is also
approved for the secondary indication in women
choosing to use an oral contraceptive as their method
of contraception, to raise folate levels for the purpose
of reducing the risk of NTDs in a pregnancy
conceived while taking the product or shortly after
discontinuing it. The primary efficacy study for
Beyaz® was a multicentre double-blind randomized
controlled US trial in 379 healthy women aged 18–40
who were treated with Beyaz® or YAZ® alone for up to
24 weeks. Beyaz® was found to increase folate levels in
the study group. In a German study of Beyaz®, folate
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levels remained elevated for several weeks following
its discontinuation.
If all oral contraceptives were fortified with folate,
they would provide the recommended minimum of
0.4 mg folate daily to the approximately 17 million
women in the United States who use this form of birth
control. Even if these women took their oral contra-
ceptives along with daily multivitamins containing
folic acid, there would be no concern about possible
overdosing, because even 1 g/day folic acid is not
considered an overdose.
“Adding folate to oral contraceptives 
is about preconceptional health 
promotion and changing pregnancy 
prevention into pregnancy planning.”
Combining folate with an oral contraceptive is of
essential importance for those with poor compliance,
since roughly 1 million women a year become preg-
nant in the United States while taking birth control
pills and half of these unintended pregnancies go to
term. By using oral contraceptives with added folate,
women would receive recommended protective doses
of folate for the crucial period before conception and
at the beginning of pregnancy; the risk of NTDs both
in planned and unplanned pregnancies would there-
fore be substantially reduced. As one-fifth of women
become pregnant within one cycle of stopping oral
contraceptive use [22], a substantial proportion of
women could not achieve protective folate levels even
if they started folic acid supplementation immedi-
ately after stopping oral contraceptives.
Of course, when women decide to stop oral contra-
ceptives and become pregnant, their health care
provider has a responsibility to counsel them about
folic acid supplementation. Adding folic acid to oral
contraceptives has the potential to increase opportu-
nities to educate providers about the importance of
folic acid as an effective, cheap and safe medicine.
Additionally, women would be exposed to messages
about folic acid on the product packaging and possi-
bly also from the pharmacist. Adding folate to oral
contraceptives is about preconceptional health
promotion and changing pregnancy prevention into
pregnancy planning.
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